Study of XNW5004 plus enzalutamide for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have metastatic prostate cancer that is still growing even with hormone therapy.
- You must have tried at least one other hormone therapy (like abiraterone) and it stopped working.
- You cannot have had enzalutamide before (except in certain parts of the study).
- You cannot have had chemotherapy for this type of cancer.
- You must have good general health and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral drug called XNW5004 in combination with other standard treatments (like abiraterone, enzalutamide, or chemotherapy) for advanced prostate cancer that has spread and is no longer controlled by hormone therapy alone. The goal is to see if these combinations work better than current options.
This trial tests a new drug (TYK-00540) combined with enzalutamide for men whose prostate cancer has spread and is no longer responding to standard hormone therapy. It may be an option if you have tried only one other newer hormone treatment and it failed.
This trial tests whether adding the drug SX-682 to enzalutamide can help men whose prostate cancer has stopped responding to other hormone treatments. You may be eligible if your cancer is growing despite treatment with abiraterone, darolutamide, apalutamide, or enzalutamide.
This trial tests a new drug called XNW34017 for people with advanced solid tumors, including small cell lung cancer and prostate cancer. It may be an option if you've tried other treatments that no longer work.
This study tests a new drug called mevrometostat combined with enzalutamide in men whose prostate cancer has spread and is no longer responding to previous hormone-blocking treatments. The goal is to see if adding mevrometostat helps slow cancer growth when enzalutamide alone is no longer working.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
Hear when a new Metastatic Castrate-Resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.